HS-AFM imaging the dynamic structure of EML4-ALK fusion oncoproteins

被引：0
|
作者：
Han, Xujun [1 ]
Kodera, Noriyuki [1 ]
Matsumoto, Kunio [2 ,3 ]
Yano, Seiji [4 ]
机构：
[1] Kanazawa Univ, Nano Life Sci Inst, Kanazawa, Japan
[2] Kanazawa Univ, Canc Res Inst, Kanazawa, Japan
[3] Kanzawa Univ, Nano LSI, Kanazawa, Japan
[4] Kanazawa Univ, Dept Respir Med, Kanazawa, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-2031
引用
收藏
页码：988 / 988
页数：1
相关论文
共 50 条
  • [41] ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene
    Isozaki, Hideko
    Ichihara, Eiki
    Yasugi, Masayuki
    Nobuaki, Ochi
    Hotta, Katsuyuki
    Takigawa, Nagio
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2014, 74 (19)
  • [42] ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
    Guan, Jikui
    Chuang, Tzu-Po
    Vikstrom, Anders
    Palmer, Ruth H.
    Hallberg, Bengt
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [43] Two novel EML4-ALK fusion variants involving EML4 exon 17 identified in lung cancer
    Li, Hai-Rong
    Sanders, Heather R.
    Sferruzza, Anthony D.
    Novic, Connie
    Meloni-Ehrig, Aurelia M.
    Albitar, Maher
    CANCER RESEARCH, 2010, 70
  • [44] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Hong Tao
    Zhe Liu
    Jing Mu
    Fei Gai
    Zhan Huang
    Liang Shi
    Diagnostic Pathology, 17
  • [45] Identification of an EML4-ALK rearrangement in an intrahepatic cholangiocarcinoma
    Favre, Loetitia
    Pujals, Anais
    Maille, Pascale
    Poullot, Elsa
    Calderaro, Julien
    PATHOLOGY INTERNATIONAL, 2021, 71 (09) : 630 - 632
  • [46] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Tao, Hong
    Liu, Zhe
    Mu, Jing
    Gai, Fei
    Huang, Zhan
    Shi, Liang
    DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [47] Therapeutic effects of an ALK inhibitor, brigatinib, on lung large cell neuroendocrine carcinoma with EML4-ALK fusion
    Suetsugu, Takayuki
    Masada, Yutaka
    Kozono, Tomoki
    Morita, Kahoru
    Yonezawa, Hajime
    Tabata, Kazuhiro
    Seki, Naohiko
    Mizuno, Keiko
    Tanaka, Kentaro
    Inoue, Hiromasa
    RESPIRATORY INVESTIGATION, 2024, 62 (06) : 1157 - 1160
  • [48] EML4-ALK fusion variant V3 confers worse survival in ALK plus NSCLC
    Christopoulos, P.
    Endris, V.
    Bozorgmehr, F.
    Elsayed, M.
    Kirchner, M.
    Ristau, J.
    Buchhalter, I.
    Penzel, R.
    Herth, F. J. F.
    Heussel, C. P.
    Eichhorn, M.
    Muley, T.
    Meister, M.
    Fischer, J. R.
    Rieken, S.
    Warth, A.
    Bischoff, H. G.
    Schirmacher, P.
    Stenzinger, A.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 105 - 105
  • [49] Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report
    Wang, Mingting
    Gong, Yifan
    Cheng, Yun
    Yang, Lei
    Wang, Wenhui
    Lei, Xiaolin
    ONCOLOGY LETTERS, 2022, 24 (04)
  • [50] Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
    Liu, Di
    Xu, Xinyan
    Wen, Junmiao
    Zhang, Chi
    Fan, Min
    LUNG CANCER, 2021, 160 : 32 - 35
12345